ÆTERNA ZENTARIS
Live / Registered — Registered (as of 29 Jun 2021)
What this means for you
Registered since 29 Jun 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90151432
- Registration number
- 6400616
- Mark type
- Design + words
- Filed
- 01 Sept 2020
- Published for opposition
- 13 Apr 2021
- Registered
- 29 Jun 2021
- Attorney of record
- Victoria Friedman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic products, conjugated or not, for the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancer, hormonal tumors, or hormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, comprising growth hormone secretagogues, ghrelin receptor agonists, ghrelin receptor antagonists, ghrelin mimetics, growth hormone analogues, growth hormone fusion proteins, growth hormone releasing hormone analogues, auto immune modulating proteins, therapeutic antibodies, small molecule kinase inhibitors, phospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical products, comprising small molecule kinase inhibitors, phospholipids, therapeutic antibodies, natural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications
Owner
- Æterna Zentaris GmbH, Frankfurt am Main, DE
- Æterna Zentaris GmbH, Frankfurt am Main, DE
- Æterna Zentaris GmbH, Frankfurt am Main, DE
Prosecution history
- 29 Jun 2021 — REGISTERED-PRINCIPAL REGISTER
- 13 Apr 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Apr 2021 — PUBLISHED FOR OPPOSITION
- 24 Mar 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Mar 2021 — ELECTRONIC RECORD REVIEW COMPLETE
- 05 Mar 2021 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 01 Mar 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Feb 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Feb 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Feb 2021 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 12 Jan 2021 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Jan 2021 — NON-FINAL ACTION E-MAILED
- 12 Jan 2021 — NON-FINAL ACTION WRITTEN
- 06 Jan 2021 — ASSIGNED TO EXAMINER
- 07 Oct 2020 — NOTICE OF DESIGN SEARCH CODE E-MAILED